Regenerative Medicine

#11

Development of novel CAR-engineered T cell products against solid and/or hematological malignancies

Chimeric antigen receptor engineered T cells (CAR-T cells) have made remarkable strides in the treatment of patients with B cell malignancies exemplified by anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL.). This success however has encountered hurdles in translation across hematological malignancies and even more so in solid tumors.

We welcome proposals aimed at the development of novel CAR-engineered T cell products against solid and/or hematological malignancies. Proposals aimed at overcoming limitations such as tumor selective expression, heterogeneous antigen expression, immunosuppressive networks in the tumor microenvironment, optimal CAR construct, T cell function and persistence, and inadequate trafficking are desired. (Also included in "Oncology")



#12 

Research and development toward realization of innovative therapeutic approach for next generation cellular cancer immuno-therapy

Remarkable new modalities of cancer therapy, like immune checkpoint inhibitors and CAR-T cells, have recently been developed and these contrast with traditional cancer therapies. In this category, Takeda are looking for innovative ideas and related technologies for cancer immunotherapy. As CAR-T cell therapy is addressed in an earlier category, in this category we are looking for new proposals that are not related to CAR-T cells but will still lead to differentiation from existing cancer therapies. (Also included in "Oncology")



#16

Development of innovative technologies to accelerate realization of novel cell therapies

Technologies related to cell therapy have been rapidly advanced and applied for clinical use, but improvements are still needed to overcome existing challenges in terms of safety and efficacy of cell therapy. Here we are seeking proposals for highly innovative technologies to accelerate clinical application of cell therapies. Areas of interest include but are not limited to:

  • New technologies using biomaterials, devices, and gene engineering etc. to enhance cell engraftment or to avoid rejection in allogeneic cell transplantation
  • Next generation safety switch (e.g. novel suicide gene system)
  • Non-invasive cell tracking system to visualize biodistribution
  • Highly sensitive system to detect unexpected undifferentiated/transformed cells in cell products

- New delivery system of transplanted cells to target tissues



#17

Development of novel method for cell growth, culture and purification with an identification of surrogate marker by understanding of cells and the cellular network

Isolation and purification of cells is required for both autologous and allogeneic cell therapies.  To manage those steps properly, we need to understand how cells grow in  culture and monitor cells via relevant assay systems in real-time.

We welcome proposals widely related to novel and highly efficient processes for growth, culture and purification of cells,  including deep understanding of cells, cellular network and interactions to identify surrogate markers for better control of differentiation or growth, mimicking the in vivo environment.



Other Areas of Interest


How to Apply

Follow the procedure below to make an application.

  1. Download the Proposal Sheet below, and complete based on the non-confidential information.

  2. Click "SUBMIT". To proceed with the application you must agree with the Terms and Conditions that are presented to you. Once you have agreed with them, click “I ACCEPT”.

  3. Complete the Application Form with your Proposal Sheet prepared at Step1 attached, and click "SUBMIT".

  4.  After submission, your website will show the “Submission Completed” page and you will receive a confirmation email.

CONTACT

Please contact the COCKPI-T® Office for further information.

COCKPI-T@takeda.co.jp

  

* Please be aware that we may not be able to respond to every inquiry.